Chemo plus immunotherapy and targeted radiation for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have rectal adenocarcinoma (confirmed by biopsy).
- Your cancer is locally advanced (spread into nearby tissue or lymph nodes) but hasn't spread to distant organs.
- You are in good general health (able to care for yourself and do light activities).
- Your major organs (blood, liver, kidneys) are working well, based on recent lab tests.
- You have not received a PD-1 inhibitor before (a type of immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.